Danaher Corporation (NYSE: DHR) delivered fourth-quarter results that exceeded analyst expectations, supported by solid performance across its healthcare and life sciences portfolio.
The company reported adjusted earnings of $2.23 per share, above estimates of $2.14, while revenue totaled $6.84 billion, exceeding the $6.79 billion consensus. Revenue rose 4.5% year over year, with non-GAAP core revenue increasing 2.5%, led by strength in bioprocessing.
For full-year 2025, Danaher posted adjusted earnings of $7.80 per share, representing 4.5% growth, on revenue of $24.6 billion, up 3.0% from the prior year. The company generated $6.4 billion in operating cash flow and $5.3 billion in non-GAAP free cash flow.
Looking ahead, Danaher said it expected low-single-digit core revenue growth in the first quarter of 2026. For the full year, the company forecast core revenue growth of 3% to 6% and adjusted earnings of $8.35 to $8.50 per share, with the midpoint slightly above the analyst consensus of $8.42.
